Anemia drug by Takeda and Affymax is submitted for FDA OK

05/31/2011 | Forbes · Pharmaceutical Business Review Online

Affymax and Takeda Pharmaceutical are seeking FDA approval of peginesatide, a drug candidate for anemia in kidney dialysis patients. The once-monthly drug, formerly called Hematide, appears as safe and effective as epoetin alfa or epoetin beta in stabilizing hemoglobin level, according to results of two Phase III trials.

View Full Article in:

Forbes · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC